65 documents

Read All
23:45 , Feb 13, 2019 |  BC Extra  |  Company News

Teva down after predicting a 'trough' year ahead

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) lost $1.49 to $17.63 on NYSE Wednesday when the company reported a decrease in 4Q18 generics sales and introduced 2019 guidance that was lower than the Street had...
Read More
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
Read More
03:49 , Aug 17, 2018 |  BC Week In Review  |  Company News

CVS to launch ICER-restricted formulary

CVS Health Corp. (NYSE:CVS) plans to offer a new formulary restricted to drugs deemed cost-effective by the Institute for Clinical and Economic Review (ICER). CVS believes the formulary will pressure manufacturers to moderate launch prices...
Read More
22:35 , Aug 14, 2018 |  BC Extra  |  Company News

CVS to launch ICER-restricted formulary

CVS Health Corp. (NYSE:CVS) plans to offer a new formulary restricted to drugs deemed cost-effective by the Institute for Clinical and Economic Review (ICER). CVS believes the formulary will pressure manufacturers to moderate launch prices...
Read More
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
Read More
20:41 , Jan 5, 2018 |  BC Week In Review  |  Company News

ICER issues affordability and access alert for tardive dyskinesia drugs

The Institute for Clinical and Economic Review issued an affordability and access alert for tardive dyskinesia drugs Ingrezza valbenazine (MT-5199, NBI-98854) and Austedo deutetrabenazine (SD-809), saying the drugs far exceed ICER’s budget impact threshold at...
Read More
19:05 , Dec 15, 2017 |  BC Week In Review  |  Company News

Teva slashing workforce amid restructuring

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv: TEVA) disclosed details of its restructuring plan, which includes reducing global headcount by 14,000 jobs, or 26%, to 39,000 over the next two years. Teva expects the cuts,...
Read More
22:29 , Dec 14, 2017 |  BC Extra  |  Company News

Teva slashing workforce amid restructuring

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv: TEVA) gained $1.60 (10%) to $17.30 in New York on Thursday after disclosing details of its restructuring plan, which includes reducing global headcount by 14,000 jobs, or 26%,...
Read More
00:32 , Nov 22, 2017 |  BC Extra  |  Politics & Policy

ICER says price of tardive dyskinesia drugs far exceed benefit

In an evidence report released Tuesday, the Institute for Clinical and Economic Review said the prices of tardive dyskinesia drugs Ingrezza valbenazine and Austedo deutetrabenazine need to be discounted by about 90% to align with...
Read More
20:22 , Nov 3, 2017 |  BioCentury  |  Regulation

Frame work

A little over four years into its implementation, FDA’s structured benefit-risk framework appears to be meeting its objectives of creating transparency into its approval decisions. The agency began to incorporate the framework templates into its...
Read More